ArticleCureus2026
Six-Month Surgical Outcomes of Ahmed ClearPath™ ST250 Implantation in Seven Eyes With Refractory Glaucoma: A Case Series.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe purpose of this study is to evaluate the short-term clinical outcomes of Ahmed ClearPath™ small tube (ST) 250 implantation in patients with refractory glaucoma.
methodsThis retrospective study included seven consecutive patients who underwent Ahmed ClearPath™ ST250 implantation at Nagoya University Hospital between December 2025 and April 2026. The primary outcome measure was intraocular pressure (IOP) at six months. Results: The mean age at surgery was 68.7 ± 17.7 years, and the median age was 74 years (range: 42-87 years). Four eyes had primary open-angle glaucoma, and one eye each had glaucoma secondary to retinal detachment surgery, uveitis, and Descemet stripping automated endothelial keratoplasty. Preoperative average IOP was 35.0 ± 6.6 mmHg, and median IOP was 32.0 mmHg (range: 28.0-45.0 mmHg). After Ahmed ClearPath
conclusionsAhmed ClearPath ST250 implantation achieved IOP reduction. These findings suggest that Ahmed ClearPath™ ST250 might be a useful surgical option for the management of refractory glaucoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.